3 completed, 2 recruiting, 1 terminated. 6 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Completed 3, Recruiting 2, Terminated 1 |
| Phase 2 | 1 | Completed 1 |
Follow Azenosertib: new trials by email Literature Review of Azenosertib trials Research Report on Azenosertib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors Azenosertib, Biopsy Procedure, Biospecimen Collection - Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Phase 1 | Recruiting | National Cancer Institute (NCI) | 48 | 2025-02-03 | 2026-10-27 |
| ZAP-IT: ZN-c3 + Carboplatin + Pembrolizumab in mTNBC Azenosertib, Carboplatin, Pembrolizumab - Breast Cancer, Breast Cancer Female | Phase 1 | Terminated | Filipa Lynce, MD | 7 | 2024-05-01 | 2026-06-04 |
| A Study of Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer Azenosertib, Niraparib - Ovarian Cancer, Platinum-resistant Ovarian Cancer | Phase 1 / Phase 2 | Completed | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | 117 | 2022-01-27 | 2026-03-18 |
| A Study of Azenosertib (ZN-c3) in Combination With Gemcitabine in Subjects With Osteosarcoma Azenosertib, Gemcitabine - Osteosarcoma | Phase 1 | Completed | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | 31 | 2021-08-01 | 2026-04-03 |
| A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer Azenosertib, Carboplatin, Pegylated liposomal doxorubicin - Solid Tumor, Epithelial Ovarian Cancer | Phase 1 | Recruiting | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | 172 | 2020-10-26 | 2026-04-07 |
| A Study of Azenosertib (ZN-c3) in Participants With Solid Tumors Azenosertib - Solid Tumor | Phase 1 | Completed | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | 274 | 2019-11-01 | 2026-03-18 |
Fallopian Tube Neoplasms (2) · Breast Neoplasms (1) · Carcinoma, Ovarian Epithelial (1) · Neoplasm Metastasis (1) · Osteosarcoma (1) · Ovarian Neoplasms (1) · Stomach Neoplasms (1) · Triple Negative Breast Neoplasms (1)
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc (4) · Filipa Lynce, MD (1) · National Cancer Institute (NCI) (1)
United States (6) · France (2) · Australia (1) · Bosnia and Herzegovina (1) · Bulgaria (1) · Georgia (1) · Serbia (1) · South Korea (1)
Filipa Lynce, MD (1) · Funda Meric-Bernstam (1)
UM1CA186688 (1)